Evidence map›Paper›PMID 40124560›Full record

ArticleDrug design, development and therapy2025

Development and Characterization of LasR Immobilized Monolithic Column for Screening Active Ingredients as Quorum Sensing Inhibitors Against

Zheng Liu, Yue Yang, Xiaoyuan Xie, Rui Li, Jifeng You, Xianglong Zhao, Yuanyuan Wang, Jialiang Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Anti-QS Strategies AgainstMicroorganisms · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zheng Liu *School of Medicine, Foshan University, Foshan, 528000, People's Republic of China.
Yue Yang *School of Medicine, Foshan University, Foshan, 528000, People's Republic of China.
Xiaoyuan XieSchool of Medicine, Foshan University, Foshan, 528000, People's Republic of China.
Rui LiSchool of Medicine, Foshan University, Foshan, 528000, People's Republic of China.
Jifeng YouSchool of Medicine, Foshan University, Foshan, 528000, People's Republic of China.ORCID 0009-0006-6166-0290
Xianglong ZhaoSchool of Medicine, Foshan University, Foshan, 528000, People's Republic of China.
Yuanyuan WangSchool of Medicine, Foshan University, Foshan, 528000, People's Republic of China.
Jialiang GuoSchool of Medicine, Foshan University, Foshan, 528000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: The enzyme/protein immobilized monolithic capillary combined with liquid chromatography-mass spectrometry is an efficient screening strategy for the corresponding agonist/antagonist. LasR is the potential therapeutic target since it plays a vital role in the colonization and invasion of Methods: Firstly, the recombinant LasR protein was prepared in Results: The recombinant active LasR protein was prepared in Conclusion: The proposed LasR immobilized monolithic column is a viable strategy in screening LasR inhibitors. It can be considered as a possible alternative to traditional methods for screening LasR inhibitors as drug candidates against

Indexed as

Anti-Bacterial AgentsBacterial ProteinsBiological ProductsPseudomonas aeruginosaQuorum SensingTrans-ActivatorsMicrobial Sensitivity TestsMolecular Docking SimulationAnti-Bacterial AgentsBacterial ProteinsBiological ProductsLasR protein, Pseudomonas aeruginosaTrans-Activatorsimmobilized LasR monolithic columnnatural productsPseudomonas aeruginosaquorum sensingscreening

Identifiers

PMID40124560
PMCPMC11929421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.